On Monday, Catalent Inc (CTLT) stock saw a decline, ending the day at $58.69 which represents a decrease of $-0.04 or -0.07% from the prior close of $58.73. The stock opened at $58.92 and touched a ...

Reports Q1 revenue $ $1.02B , consensus $1.06B…Q1’25 Adjusted EBITDA of $125 million increased 11% as reported, or 10% in constant ...

Catalent (CTLT) delivered earnings and revenue surprises of -218.18% and 5.28%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Catalent's revenue for fiscal first quarter ended Sept. 30 was $1.02 billion, marginally below analysts' estimates of $1.06 ...

Catalent (NYSE:CTLT), a contract development and manufacturing organization (CDMO), reported results for Q1 of fiscal 2025 that missed analyst expectations.

Catalent Inc. (CTLT) announced Loss for first quarter that decreased from last year The company's bottom line totaled -$129 million, ...

(CTLT) on Tuesday reported a loss of $129 million in its fiscal first quarter. The Somerset, New Jersey-based company said it had a loss of 71 cents per share. Losses, adjusted for one-time gains and ...

BRUSSELS/LONDON (Reuters) -EU antitrust regulators will decide by Dec. 6 whether to clear Novo Holdings' acquisition of ...

Jeff Stute, a veteran investment banker with a career spanning three decades at Perella Weinberg Partners and JPMorgan Chase ...

Catalent, Inc. (CTLT), headquartered in Somerset, New Jersey, is a significant provider in the pharmaceutical and biotech ...

Roche CEO opposes Novo Nordisk's acquisition of Catalent, citing concerns about competition in the ...

FRANKFURT (Reuters) -The CEO of pharmaceuticals giant Roche said authorities should block the takeover of contract drug ...